Anti-BRD3 antibody - C-terminal,Abcam,AB228936

Target data Chromatin reader that recognizes and binds acetylated histones, thereby controlling gene expression and remodeling chromatin structures (PubMed : 18406326, PubMed : 22464331, PubMed : 27105114, PubMed : 32895492). Recruits transcription factors and coactivators to target gene sites, and activates RNA polymerase II machinery for transcriptional elongation (PubMed : 29567837, PubMed : 32895492). In vitro, binds acetylated lysine residues on the N-terminus of histone H2A, H2B, H3 and H4 (PubMed : 18406326). Involved in endoderm differentiation via its association with long non-coding RNA (lncRNA) DIGIT : BRD3 undergoes liquid-liquid phase separation upon binding to lncRNA DIGIT, promoting binding to histone H3 acetylated at 'Lys-18' (H3K18ac) to induce endoderm gene expression (PubMed : 32895492). Also binds non-histones acetylated proteins, such as GATA1 and GATA2 : regulates transcription by promoting the binding of the transcription factor GATA1 to its targets (By similarity). See full target information BRD3